Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed week 24 evaluation of Study C935788-047 or Study C935788-048 or discontinued early due to lack of response.~* Able and willing to give written informed consent~Exclusion Criteria:~* Discontinued participation in Study C935788-047 or Study C935788-048 for any reason other than lack of response~* Poorly controlled hypertension during Study C935788-047 or Study C935788-048~* Significant infection, an acute infection such as influenza, or known inflammatory process

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fostamatinib Disodium (Type: EXPERIMENTAL): Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).